Standardized Diagnosis and Treatment of Endocrine Hypertension

September 12, 2023 updated by: Affiliated Hospital of Nantong University
Cases of endocrine hypertension or primary hypertension who have signed informed consent will be collected. Patients with endocrine hypertension will be divided into surgical treatment group and drug treatment group according to actual treatment situation. A database will be established for all patients. The investigators will comprehensively evaluate the general conditions, past medical history, metabolic and biochemical indicators, psychological status, cardiovascular risk factors. All the patients will be followed up for 12 months at baseline, 6 months and 12 months. Clinical data and specimen will be collected.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The investigators will collect 100 patients with secretory hypertension and 100 patients with essential hypertension. Patients with endocrine hypertension will be divided into surgical treatment group and drug treatment group according to actual treatment situation. Resected specimens from surgical patients will be used for immunohistochemistry and western blot. A database will be established for all patients to assess their general situation, past medical history, metabolic and biochemical indicators, psychological status, cardiovascular risk factors, etc. The investigators expect to find more accurate screening indicators from blood and urine specimens. All the patients will be followed up for 12 months at baseline, 6 months and 12 months. Blood pressure, degree of atherosclerosis, biochemical markers, hormone levels and cardiac function indicators will be measured at three time points.

Study Type

Observational

Enrollment (Estimated)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
    • Jiangsu
      • Nantong, Jiangsu, China, 226001
        • Recruiting
        • Gu Yunjuan
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with endocrine hypertension or primary hypertension treated at Affiliated Hospital of Nantong University between 2021 and 2024

Description

Inclusion Criteria:

age≥18 years

Exclusion Criteria:

  1. myocardial infarction
  2. congestive heart failure
  3. stroke

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
patients with EH
patients with endocrine hypertension
Procedure: Standardized diagnosis and treatment
Patients with endocrine hypertension undergo surgery or medication depending on the cause after completion of standard diagnostic procedures. Patients with primary hypertension receive medication.
Other Names:
  • antihypertensive drugs
patients with PH
patients with primary hypertension

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The control rate of blood pressure
Time Frame: 12 months
The investigators will compare the proportion of patients with blood pressure below 140/90 mmHg after different treatments.
12 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes of carotid imima-media thickness
Time Frame: 12 months
Carotid ultrasound will be used to observe the changes of carotid intima-media thickness after different treatments.
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Affiliated Hospital of Nantong University

Investigators

  • Principal Investigator: Gu Yunjuan, M.D/Ph.D, Affiliated Hospital of Nantong University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 1, 2021

Primary Completion (Estimated)

January 31, 2024

Study Completion (Estimated)

July 1, 2024

Study Registration Dates

First Submitted

November 25, 2021

First Submitted That Met QC Criteria

November 25, 2021

First Posted (Actual)

December 8, 2021

Study Record Updates

Last Update Posted (Actual)

September 13, 2023

Last Update Submitted That Met QC Criteria

September 12, 2023

Last Verified

August 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Endocrine Hypertension

Clinical Trials on Standardized diagnosis and treatment

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe